Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals ...

We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

Premier products in Merck’s portfolio include Keytruda ... Merck & Co., Inc. (NYSE:MRK) is in 29th position on our list of 31 ...

We recently published a list of 10 Best Healthcare Stocks ... and animal health products. At its core, Merck is in the business of improving human and animal health through scientific innovation.

Merck has secured the option to license the vaccines for up to $10 million next year. If the drugmaker takes up that option, Evaxion will be in line to receive up to $592 million per product.

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...

Merck's P/S multiple is roughly 4, and its P/FCF is 21. That makes its valuation a bit pricier than Pfizer's per dollar of revenue, but significantly cheaper per dollar of free cash flow. In other ...

The price of ethereum, or 1 ETH, was $2,704.70 as of 8 a.m. ET. The crypto’s highest intraday price in the past year was ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...